159 related articles for article (PubMed ID: 32896015)
1. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
Kim SY; Kim SM; Chang H; Chang HS; Park CS; Lee YS
Head Neck; 2020 Dec; 42(12):3678-3684. PubMed ID: 32896015
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Anticancer Activity of
Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
[TBL] [Abstract][Full Text] [Related]
4. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.
Park KC; Kim SM; Jeon JY; Kim BW; Kim HK; Chang HJ; Lee YS; Kim SY; Choi SH; Park CS; Chang HS
Neoplasia; 2017 Mar; 19(3):145-153. PubMed ID: 28142087
[TBL] [Abstract][Full Text] [Related]
7. PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.
Zhu W; Xie B
Cancer Biol Ther; 2023 Dec; 24(1):2223383. PubMed ID: 37351847
[TBL] [Abstract][Full Text] [Related]
8. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ
Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266
[TBL] [Abstract][Full Text] [Related]
10. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
[TBL] [Abstract][Full Text] [Related]
11. Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
Aoyama M; Takizawa H; Otani T; Inoue S; Kawakita N; Tsuboi M; Bando Y; Uehara H; Kondo K; Tangoku A
Oncol Rep; 2020 Oct; 44(4):1709-1716. PubMed ID: 32945510
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer.
Choi KH; Jeon JY; Lee YE; Kim SW; Kim SY; Yun YJ; Park KC
Transl Oncol; 2019 Feb; 12(2):381-388. PubMed ID: 30522045
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Mortensen ACL; Berglund H; Hariri M; Papalanis E; Malmberg C; Spiegelberg D
Sci Rep; 2023 Oct; 13(1):16844. PubMed ID: 37803074
[TBL] [Abstract][Full Text] [Related]
15. Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells.
Allegri L; Capriglione F; Maggisano V; Damante G; Baldan F
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360846
[TBL] [Abstract][Full Text] [Related]
16. Potent antitumor activity of novel taxoids in anaplastic thyroid cancer.
Wang M; Wang C; Feng C; Guo W; Chen H; Liu B; Li E; Liu W; Taouil A; Ojima I; Hou P
Endocrine; 2022 Feb; 75(2):465-477. PubMed ID: 34591230
[TBL] [Abstract][Full Text] [Related]
17. The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2015 Apr; 48(3):886-93. PubMed ID: 25096912
[TBL] [Abstract][Full Text] [Related]
18. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
Mi L; Liu J; Zhang Y; Su A; Tang M; Xing Z; He T; Wei T; Li Z; Wu W
Phytomedicine; 2024 Jul; 129():155670. PubMed ID: 38704915
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
20. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
Yeung SC; Xu G; Pan J; Christgen M; Bamiagis A
Cancer Res; 2000 Feb; 60(3):650-6. PubMed ID: 10676649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
